Single-cell sequencing identifies Cytoskeleton-Associated Protein 4 as a novel modulator of cardiac fibroblast activation, highlighting a potential new therapeutic target for heart disease.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for antifibrotic therapies in heart disease; leaves open clinical translation from animal data.
Gladka et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: